279 related articles for article (PubMed ID: 37833617)
41. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
42. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
Craiglow B; Lee YW; Vañó-Galván S; Egeberg A; Dutronc Y; Durand F; Pierce E; Yu G; Chen YF; Mostaghimi A
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38904749
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date.
Faria S; Freitas E; Torres T
Drugs Context; 2023; 12():. PubMed ID: 37781168
[TBL] [Abstract][Full Text] [Related]
44. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.
Husein-ElAhmed H; Husein-ElAhmed S
J Eur Acad Dermatol Venereol; 2024 May; 38(5):835-843. PubMed ID: 38279559
[TBL] [Abstract][Full Text] [Related]
45. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
46. Alopecia Areata: Current Treatments and New Directions.
Dahabreh D; Jung S; Renert-Yuval Y; Bar J; Del Duca E; Guttman-Yassky E
Am J Clin Dermatol; 2023 Nov; 24(6):895-912. PubMed ID: 37606849
[TBL] [Abstract][Full Text] [Related]
47. Application of Baricitinib in Dermatology.
Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
[TBL] [Abstract][Full Text] [Related]
48. [Janus kinase inhibitors for the treatment of alopecia areata].
Kobal I; Ramot Y
Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
[TBL] [Abstract][Full Text] [Related]
49. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
50. European expert consensus statement on the systemic treatment of alopecia areata.
Rudnicka L; Arenbergerova M; Grimalt R; Ioannides D; Katoulis AC; Lazaridou E; Olszewska M; Ovcharenko YS; Piraccini BM; Prohic A; Rakowska A; Reygagne P; Richard MA; Soares RO; Starace M; Vañó-Galvan S; Waskiel-Burnat A
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):687-694. PubMed ID: 38169088
[TBL] [Abstract][Full Text] [Related]
51. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
[TBL] [Abstract][Full Text] [Related]
53. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib.
Tang GT; Triwongwaranat D; Sinclair R; Joseph S; Eisman S; Rathnayake D; Varathan V; Trindade de Carvalho L; Bhoyrul B
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38270233
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
[TBL] [Abstract][Full Text] [Related]
55. JAK inhibitors for alopecia areata: a systematic review and meta-analysis.
Phan K; Sebaratnam DF
J Eur Acad Dermatol Venereol; 2019 May; 33(5):850-856. PubMed ID: 30762909
[TBL] [Abstract][Full Text] [Related]
56. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
57. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
58. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
Bushwereb R; Srivastava G
Ital J Dermatol Venerol; 2024 May; ():. PubMed ID: 38780910
[TBL] [Abstract][Full Text] [Related]
59. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
60. The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions.
Donovan J
Skin Therapy Lett; 2023 May; 28(3):1-7. PubMed ID: 37339501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
